You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

~ Buy the OMIDRIA (ketorolac tromethamine; phenylephrine hydrochloride) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR OMIDRIA


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for OMIDRIA

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02895035 ↗ Comparison of Epinephrine and Phenylephrine/Ketorolac With Regards to Pupil Size Terminated Milton S. Hershey Medical Center Phase 4 2016-09-01 The objective of this study is to compare the maintenance of intraoperative mydriasis during cataract surgery between two drugs: epinephrine, which has routinely been used for decades, and Omidria, a newly FDA approved combination drug of phenylephrine and ketorolac. Patients undergoing cataract surgery that are enrolled in the trial will randomly receive one of the drugs in one eye, and the other eye will receive the drug during the subsequent cataract surgery.
NCT03864133 ↗ No Drop Post-Op Cataract Surgery Completed Omeros Corporation Phase 4 2019-07-08 This study evaluates the effect of Intraocular Phenylephrine/Ketorolac Infusion on Retinal Thickness and Macular Edema in Cataract Surgery. Participants will receive infusions of Phenylephrine/Ketorolac during surgery instead of receiving topical NSAID drops pre and post operatively.
NCT03864133 ↗ No Drop Post-Op Cataract Surgery Completed Wake Forest University Health Sciences Phase 4 2019-07-08 This study evaluates the effect of Intraocular Phenylephrine/Ketorolac Infusion on Retinal Thickness and Macular Edema in Cataract Surgery. Participants will receive infusions of Phenylephrine/Ketorolac during surgery instead of receiving topical NSAID drops pre and post operatively.
NCT04316936 ↗ Omidria and Dexycu, or Omidria and Dextenza Compared to Topical Prednisolone Acetate 1% Following Cataract Surgery Recruiting Ocular Therapeutix, Inc. Phase 4 2019-12-10 This research will evaluate the efficacy of Omidria and Dexycu, Omidria and Dextenza, and Omidria and prednisolone acetate 1% in the resolution of post-operative inflammation and pain following cataract surgery.
NCT04316936 ↗ Omidria and Dexycu, or Omidria and Dextenza Compared to Topical Prednisolone Acetate 1% Following Cataract Surgery Recruiting Silverstein Eye Centers Phase 4 2019-12-10 This research will evaluate the efficacy of Omidria and Dexycu, Omidria and Dextenza, and Omidria and prednisolone acetate 1% in the resolution of post-operative inflammation and pain following cataract surgery.
NCT04829799 ↗ Effect of Intracameral Phenylephrine/Ketorolac on Intraoperative Pain Not yet recruiting Omeros Corporation Phase 4 2021-08-01 To compare the effect of intraoperative intracameral Omidria (Phenylephrine and Ketorolac 1.0%/0.3%) verses 1% Lidocaine on pain reduction during and after cataract surgery.
NCT04829799 ↗ Effect of Intracameral Phenylephrine/Ketorolac on Intraoperative Pain Not yet recruiting University of Florida Phase 4 2021-08-01 To compare the effect of intraoperative intracameral Omidria (Phenylephrine and Ketorolac 1.0%/0.3%) verses 1% Lidocaine on pain reduction during and after cataract surgery.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for OMIDRIA

Condition Name

Condition Name for OMIDRIA
Intervention Trials
Cataract 3
Cataract Surgery 1
Cystoid Macular Edema 1
Eye Diseases 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for OMIDRIA
Intervention Trials
Cataract 4
Retinal Diseases 1
Macular Edema 1
Lens Diseases 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for OMIDRIA

Trials by Country

Trials by Country for OMIDRIA
Location Trials
United States 2
Germany 1
Austria 1
Portugal 1
Netherlands 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for OMIDRIA
Location Trials
Missouri 1
North Carolina 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for OMIDRIA

Clinical Trial Phase

Clinical Trial Phase for OMIDRIA
Clinical Trial Phase Trials
Phase 4 4
Phase 3 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for OMIDRIA
Clinical Trial Phase Trials
Recruiting 2
Terminated 1
Completed 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for OMIDRIA

Sponsor Name

Sponsor Name for OMIDRIA
Sponsor Trials
Omeros Corporation 2
Wake Forest University Health Sciences 1
Ocular Therapeutix, Inc. 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for OMIDRIA
Sponsor Trials
Other 6
Industry 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.